Table 1 Patient, tumor an treatment characteristics
All Patients | |
|---|---|
N | 99 (%) |
Age, years | |
median | 67.4 |
range | 43–88 |
Gender | |
male | 62 (63%) |
female | 37 (37%) |
Tobacco consumption | |
median PY | 40 |
range | 0–150 |
Atelectasis before RT | 10 (10%) |
Tumor Histology | |
Adenocarcinoma | 49 (50%) |
SCC | 42 (42%) |
NOS | 8 (8%) |
ECOG performance status | |
0 | 48 (48%) |
1 | 51 (52%) |
Lung function testing | |
Fev1 median (range) | 2.2 l/81% (1.05–3.79 l) |
DLCO | 57% (range: 22–93) |
UICC 7th edition Stage | |
IIIA | 44 (44%) |
IIIB | 55 (56%) |
T-Stage (UICC 7th edition) | |
unknown | 2 (2%) |
1 | 10 (10%) |
2 | 17 (17%) |
3 | 30 (30%) |
4 | 40 (41%) |
N-Stage (UICC 7th edition) | |
0 | 10 (10%) |
1 | 9 (9%) |
2 | 36 (36%) |
3 | 44 (45%) |
Tumor localisation | |
central | 40 (40%) |
pancoast | 7 (7%) |
lobular | 52 (53%) |
PET-CT | |
before CRT | 93 (94%) |
after CRT | 35 (35%) |
Gross tumor volume (ccm) | |
mean | 109.9 |
median | 85.3 |
range | 3–434 |
Chemotherapy | |
Concurrent or sequential CRT | 88 (89%) |
Induction chemotherapy | 52 (53%) |
Concurrent chemotherapy | 77 (78%) |
Radiation Technique | |
3D-conformal | 59 (60%) |
IMRT | 40 (40%) |
Total Dose | |
Mean | 62.4Gy |
Median | 66Gy |
< 54 | 13 (13%) |
54.01–60 | 19 (19%) |
60.01–66 | 58 (59%) |
> 66.01 | 9 (9%) |
CRT completed as planned | 94 (95%) |